drugset / Trial / NCT04669158
Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis
Phase 1/2
Completed
53 enrolled
Stanford University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a randomized, placebo-controlled phase 1/2a study to investigate the safety and tolerability of Idebenone in patients 18 years of age or older with non-alcoholic steatohepatitis, with stage 1-3 fibrosis. As secondary end point target engagement and fibrosis improvement will be assessed.
Timeline
- Start
- 2021-07-30
- Primary completion
- 2023-07-05
- Completion
- 2023-07-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Idebenone | Small molecule | 200 mg | Oral |